Early mixed chimerism-based preemptive immunotherapy in children undergoing allogeneic hematopoietic stem cell
Biljana Horn1, Justin T Wahlstrom1, Alexis Melton1
1Division of Pediatric Allergy, Immunology and Bone Marrow Transplantation at University of California San Francisco (UCSF) Benioff Children's Hospital, San Francisco, California.
Abstract:
This retrospective analysis comprises 10-year experience with early posttransplant mixed chimerism-based preemptive intervention. Out of 104 patients, 51 received preemptive immunotherapy. Their outcomes were similar to patients achieving full donor chimerism spontaneously. Among patients receiving intervention, 5-year event-free survival was identical in patients with and without pretransplant residual disease, respectively (68% [95% confidence interval (CI) 38-98%] vs. 69% [95% CI 54-85%] log-rank = 0.4). In patients who received preemptive immunotherapy, chimerism status and residual disease prior to transplant were no longer predictors of poor outcome; however, 41% of the patients with residual disease prior to transplant relapsed early and did not benefit from this strategy.
